NTRB Share Price Performance
US$6.92
1.95 (39.24%)
Price US$6.92
Share PriceUS$6.92
NTRB Community Narratives
There are no narratives available yet.
Recent NTRB News & Updates
No updates
Nutriband Inc. Key Details
Last Reported Earnings
Apr 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.90
- Gross Margin
- 34.63%
- Net Profit Margin
- -415.83%
- Debt/Equity Ratio
- 3.5%
Nutriband Inc. Competitors
About NTRB
- Founded
- 2016
- Employees
- n/a
- CEO
- WebsiteView website
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading